GLAD-AML – Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Condition(s):ACUTE MYELOID LEUKEMIALast Updated:October 15, 2021Terminated
Hide Studies Not Open or Pending
Condition(s):ACUTE MYELOID LEUKEMIALast Updated:October 15, 2021Terminated
Condition(s):Acute Myeloid Leukemia (AML)Last Updated:June 29, 2023Active, not recruiting
Condition(s):Relapsed/Refractory Acute Myeloid LeukemiaLast Updated:February 8, 2023Terminated
Condition(s):Acute Myeloid LeukemiaLast Updated:April 6, 2020Completed
Condition(s):Acute Lymphocytic Leukemia; Acute Myeloid LeukemiaLast Updated:May 16, 2017Completed
Condition(s):Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)Last Updated:October 12, 2016Completed
Condition(s):Allogenic Stem Cell TransplantationLast Updated:March 5, 2024Withdrawn
Condition(s):Acute Myeloid LeukemiaLast Updated:June 18, 2023Recruiting
Condition(s):Recurrent, Refractory, or High Risk Leukemias; Matched Targeted TherapyLast Updated:November 1, 2023Active, not recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:July 28, 2015Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.